Pourbaghi, M.; Haghani, L.; Zhao, K.; Karimi, A.; Marinelli, B.; Erinjeri, J.P.; Geschwind, J.-F.H.; Yarmohammadi, H.
Anti-Glycolytic Drugs in the Treatment of Hepatocellular Carcinoma: Systemic and Locoregional Options. Curr. Oncol. 2023, 30, 6609-6622.
https://doi.org/10.3390/curroncol30070485
AMA Style
Pourbaghi M, Haghani L, Zhao K, Karimi A, Marinelli B, Erinjeri JP, Geschwind J-FH, Yarmohammadi H.
Anti-Glycolytic Drugs in the Treatment of Hepatocellular Carcinoma: Systemic and Locoregional Options. Current Oncology. 2023; 30(7):6609-6622.
https://doi.org/10.3390/curroncol30070485
Chicago/Turabian Style
Pourbaghi, Miles, Leila Haghani, Ken Zhao, Anita Karimi, Brett Marinelli, Joseph P. Erinjeri, Jean-Francois H. Geschwind, and Hooman Yarmohammadi.
2023. "Anti-Glycolytic Drugs in the Treatment of Hepatocellular Carcinoma: Systemic and Locoregional Options" Current Oncology 30, no. 7: 6609-6622.
https://doi.org/10.3390/curroncol30070485
APA Style
Pourbaghi, M., Haghani, L., Zhao, K., Karimi, A., Marinelli, B., Erinjeri, J. P., Geschwind, J.-F. H., & Yarmohammadi, H.
(2023). Anti-Glycolytic Drugs in the Treatment of Hepatocellular Carcinoma: Systemic and Locoregional Options. Current Oncology, 30(7), 6609-6622.
https://doi.org/10.3390/curroncol30070485